Masimo Corporation

NASDAQ:MASI

Medical - Devices

Healthcare
$179.95 +0.00%

+$0.00 today

Market cap
$9.42B
Beta
1.10
P/E (TTM)
123.1
EPS (TTM)
$1.46
52W Low $125.94High $179.99

Volume 0.00M

Average 1.08M

MASI Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Masimo CorporationNASDAQ: MASI

Stock-Based Compensation · Q1 FY2026 · quarter ended Apr 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $8.9M fell 2.2% year over year, ahead of the -37.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -9.1% a year.

Context

  • Stock-based compensation amounted to 2.3% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -2.2% holds above the trailing-twelve-month pace of -37.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterApr 2026
$8.9M+0.0% QoQ
Last fiscal yearJan 2026
$35.8M-13.7% YoY
LTMApr 2026
$26.3M-37.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.2%——
1 year-13.7%——
3-year CAGR-9.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
35.8M USD
Year-over-year change
-13.7%
4-year CAGR
-5.4%

Stock-Based Compensation vs competitors

How MASI compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -37.2% is the 9th highest of 10, against a peer median of -13.7%.
  • Stock-based compensation amounts to 1.7% of revenue for MASI, versus a peer median of 1.0%.
MASI Competitors
Stock-Based Compensation for MASI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BAXBaxter International Inc.LTM Jun 2026$115M USD-5.7%-5.8%1.0%
MOHMolina Healthcare, Inc.LTM Sep 2026$105M USD+133.3%-23.0%0.2%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$93.45M USD+60.8%+49.9%33.3%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$45.8M USD+43.1%-1.6%1.8%
AVTRAvantor, Inc.LTM Jun 2026$42.5M USD-16.5%+0.4%0.6%
ATRAptarGroup, Inc.LTM Jun 2026$40.84M USD-13.7%—1.0%
RGENRepligen CorporationLTM Jun 2026$33.29M USD-26.1%+6.1%4.2%
HSICHenry Schein, Inc.LTM Jun 2026$29M USD-17.1%—0.2%
MASIMasimo CorporationLTM Apr 2026$26.3M USD-37.2%-9.1%1.7%
ABVXAbivax S.A.FY2025€0 EUR-100.0%——
STVNStevanato Group S.p.A.LTM Jun 2026€0 EUR——0.0%
Peer median (excluding MASI) —-13.7%-0.6%1.0%

Competitors are the stored peer set for MASI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Jan 2026
Net Income229.6M143.5M81.5M(304.9M)(151.5M)
Depreciation & Amortization35.6M136.1M98.3M103M38.8M
Deferred Income Tax(15.1M)(39.3M)(35.6M)(38.2M)11.8M
Stock-Based Compensation44.7M47.7M7M41.5M35.8M
Change in Working Capital(31.5M)(261.8M)(70.9M)(10.7M)(89.9M)
Accounts Receivables(76.9M)(151.3M)91.9M(60.2M)17.2M
Inventory13.5M(155.9M)(69.2M)(7.5M)(112.1M)
Accounts Payables11M60.5M(19.6M)14.8M(27.1M)
Other Working Capital20.9M(15.1M)(74M)42.2M32.1M
Other Non-Cash Items1.3M3.2M13.8M405.7M372.2M
Operating Cash Flow264.6M29.4M94.1M196.4M217.2M
Capital Expenditures(34.9M)(56.3M)(87.7M)(51.1M)(19.4M)
Acquisitions (Net)0(999.7M)7.5M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(12M)(5.2M)(44.7M)(31.2M)294.5M
Investing Cash Flow(37.5M)(1.06B)(81.2M)(51.2M)275.1M
Debt Repayment0939.2M(51.2M)(146.8M)(207.8M)
Common Stock Issued23.2M8.1M7M25.2M71.4M
Common Stock Repurchased(128.9M)(401.5M)00(363.7M)
Dividends Paid00000
Other Financing Activities(16.7M)(25.4M)(12.9M)(4M)(20.6M)
Financing Cash Flow(122.4M)520.4M(57.1M)(125.6M)(520.7M)
Effect of Forex Changes(1.3M)(30.9M)2.8M(6.4M)53.8M
Net Change in Cash103.4M(538.8M)(41.4M)13.2M26M
Free Cash Flow229.7M(26.9M)6.4M145.3M197.8M

Masimo Corporation

NASDAQ:MASI

Intrinsic Alpha fair value

Locked

Current Price

$179.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.